Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled Study

• Status: Completed
• Trial end date: 2015-10-01
• Target enrollment: 0
• Participant gender: All

Summary

IgA nephropathy is the most common type of primary glomerulonephritis and might caused by deposition of immune complex containing IgA in mesangium and causing local immune activation. Hydroxychloroquine reduces the activation of dendritic cells and the inflammatory process and showed the potential effect of treatment of patients with IgA nephropathy.

The investigators study will recruite IgA nephropathy patients with proteinuria range from 0.75 to 3.5g/d even after three-month treatment by sufficient ACEi/ARB. The patients were treated with Hydroxychloroquine 300-400mg/d according to eGFR. The proteinuria will recorded every two months and total four months. Then, the drug will be stopped for two months for observation of change of proteinuria.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: LLiu
• Treatments: Hydroxychloroquine

Criteria

Inclusion Criteria:

1. primary IgA nephopathy

2. age 18-75 years

3. proteinuria range from 0.75 to 3.5g/d even after three-month treatment by sufficient ACEi/ARB

4. eGFR>30ml/min/1.73m2

Exclusion Criteria:

1. immune suppressive agent in recent one years

2. crescent glomerulonephritis, might use immune suppressive agent

3. chronic hepatic disease

4. myocardial infarction

5. malignant hypertension

6. stroke

7. malignant tumor

8. retinopathy

9. other contraindication of Hydroxychloroquine

10. pregnancy and breastfeeding women

11. life expectancy for less than 6 months

12. in other clinical trials

13. not suitable for the study judged by investigator